Publications by authors named "Roel Funke"

Claim this Profile
N
Non-viral precision T cell receptor replacement for personalized cell therapy.
Susan P Foy, Kyle Jacoby, Daniela A Bota, Theresa Hunter, Zheng Pan, Roel Funke

Nature· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Sylvia Adams, Jennifer R Diamond, Erika Hamilton, Paula R Pohlmann, Sara M Tolaney, Roel Funke

JAMA Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
David R Spigel, Jamie E Chaft, Scott Gettinger, Bo H Chao, Luc Dirix, Roel Funke

J Thorac Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Roel Funke

N Engl J Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Marcin Kowanetz, Wei Zou, Scott N Gettinger, Hartmut Koeppen, Mark Kockx, Roel Funke

Proc Natl Acad Sci U S A· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Stephen V Liu, D Ross Camidge, Scott N Gettinger, Giuseppe Giaccone, Rebecca S Heist, Roel Funke

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Roel Funke

Oncologist· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Roel Funke

Oncologist· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, Mario Sznol, Konstanty Korski

Nat Commun· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
M Catherine Pietanza, Thomas James Lynch, Primo N Lara, John Cho, Ronald H Yanagihara, Roel Funke

J Thorac Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Torsten Trowe, Sotiria Boukouvala, Keith Calkins, Richard E Cutler, Ryan Fong, Roel Funke

Clin Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular analysis of the acetolactate synthase gene of Chlamydomonas reinhardtii and development of a genetically engineered gene as a dominant selectable marker for genetic transformation.
Joy L Kovar, Jun Zhang, Roel P Funke, Donald P Weeks

Plant J· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis